The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Congress Urged to Fix CMS Rule Distorting Part B Drug Reimbursement

Congress Urged to Fix CMS Rule Distorting Part B Drug Reimbursement

February 1, 2018 • By Kelly Tyrrell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LATE-BREAKING NEWS

You Might Also Like
  • Final 2019 Physician Reimbursement Rule Released by CMS Includes Victories for Rheumatology
  • CMS Rule Reflects ACR’s Advocacy, but More Patient Protections Needed
  • The ACR Lobbies Against New Part B Drug Cost Adjustment Rule
Also By This Author
  • ACR Addresses the Rheumatology Workforce Shortage

Editor’s note: The ACR praises Congressional leaders for passing today’s (2/9) sweeping spending agreement, which includes a technical provision reversing a Centers for Medicare & Medicaid Services (CMS) policy that would have linked physicians’ quality payment adjustments to Medicare Part B drug costs starting in 2019. The ACR also applauded the inclusion of provisions that permanently repeal Medicare caps on outpatient therapies and other rehabilitation services, repeal the Independent Payment Advisory Board (IPAB) and eliminate the Medicare Part D donut hole.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

When Congress signed the Medicare Access and CHIP Reauthorization Act (MACRA) into law in April 2015, leaders of both parties celebrated a rare bipartisan achievement. But late last year, the CMS announced a rule through MACRA’s Merit-Based Incentive Payment pathway that would both consider Medicare Part B drugs costs when determining cost scores for reimbursement, as well as apply the MIPS penalties or bonuses to reimbursements for Part B drug costs. In 2019, providers will be subject to a 4% positive or negative adjustment calculated across several categories, including cost.

The ACR and many other physician groups believe the application of the adjustment is not in line with the goals of MACRA and could make it more difficult for physicians, particularly those in small practices and in rural settings, to administer Part B medications in their communities, thus creating another patient access issue.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR’s Response
The ACR is a leader of a broad coalition of provider and patient groups, also led by the American Academy of Ophthalmology (AAO) and American Society of Clinical Oncology (ASCO), pushing Congress to reverse the CMS policy. If not fixed, rheumatologists and other specialist providers could be penalized for providing Part B drugs beginning in 2019. But legislators have been reluctant to open it back up, says ACR Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP.

“CMS finalized its decision to move this new policy forward in November 2017 despite strong congressional opposition,” Dr. Worthing says. “This means it will take an act of Congress to fix the problem and change CMS policy.

“That’s exactly what we’re aiming for,” he adds.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Although rheumatology is a small specialty, the ACR has taken robust leadership on this issue. For example, on Jan. 18, the ACR co-authored a letter to relevant House and Senate committee members to urge a fix.1 The ACR helped garner more than 100 organizational co-signers across the country, including the American Academy of Dermatology, American Academy of Neurology, American College of Gastroenterology, National Psoriasis Foundation, Arthritis Foundation and many others, including state and local rheumatology societies.

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Practice Management Tagged With: Centers for Medicare and Medicaid Services (CMS), Medicare Access and CHIP Reauthorization Act (MACRA), Medicare Part B payments, Merit-Based Incentive Payment (MIPS) pathway, Part B drug ruling, Regulatory Relief Coalition

You Might Also Like:
  • Final 2019 Physician Reimbursement Rule Released by CMS Includes Victories for Rheumatology
  • CMS Rule Reflects ACR’s Advocacy, but More Patient Protections Needed
  • The ACR Lobbies Against New Part B Drug Cost Adjustment Rule
  • ACR Praises Congress for Bill with Part B Fix, Therapy Caps Repeal

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.